Published by ChinaMNC · Qiubei

Yunnan’s Five-Year Plan for Traditional Chinese Medicine Herbs: What Foreign Founders Should Know

Yunnan’s 15th Five-Year Plan for Chinese medicinal herb development targets a smaller planting footprint but higher output value by 2030, with priority varieties, GAP bases, under-forest cultivation, processing upgrades, market safeguards and AI tools. Foreign founders should read it as a signal of provincial priorities for cultivation, processing and health-product ventures.

Yunnan’s Herb Plan at a Glance

Yunnan Province has published a plan for the development of its Chinese medicinal herb industry during the 15th Five-Year Plan period. The document sets out targets and policy directions through 2030. For foreign founders considering a China-registered company in agriculture, processing, health products or related services, the plan is a useful indicator of where provincial support and regulatory attention are likely to focus.

The headline target is a deliberate shift in scale. By 2030, the planted area for Chinese medicinal herbs in Yunnan is expected to fall by 1.608 million mu, while the comprehensive output value is targeted to rise by RMB 50 billion. The stated logic is to trade a reduction in area for gains in quality, processing, branding and efficiency.

Priority Varieties and Crop Layout

The plan builds on the 156 varieties listed in the 2024 edition of Yunnan’s catalogue of authentic regional medicinal materials. It groups future development into three categories.

• Authentic advantage varieties: the “Top Ten Yunnan Medicines,” led by sanqi (Panax notoginseng). The list also includes Dian heavy楼 (Paris polyphylla), fleabane, Dendrobium officinale, amomum fruit, gastrodia, Yunnan poria, Yunnan angelica, Yunnan costus and Yunnan gentian.
• Health-oriented specialty varieties: the “Top Ten Health Resources,” namely Yunnan polygonatum, safflower, bletilla, purple-skin Dendrobium, emblica (Yunnan olive), coix seed, chebula, tsaoko, ginger and star anise.
• Potential cultivation varieties: the “Six Southern Medicines,” namely amomum fruit, dragon’s blood, cibotium, agarwood, kidney tea and Dai bai jie.

For founders, this taxonomy matters because it signals which species provincial authorities intend to prioritise. A venture focused on one of these varieties may find clearer policy alignment than one working on species outside the lists.

Standardised Cultivation and GAP Bases

The plan aims to build 200 Good Agricultural Practice (GAP) bases for Chinese medicinal herbs. A key focus is full GAP coverage for Wenshan sanqi bases. The province also intends to advance GAP bases in an orderly way for under-forest varieties such as poria, amomum fruit, tsaoko and phellodendron, and to compete for national-level high-standard raw material production bases.

Foreign founders should note that GAP is a cultivation standard, not a company registration category. A China-registered entity involved in growing, contracting or sourcing herbs may need to understand how GAP base status affects supply relationships and buyer requirements. The plan’s emphasis on GAP suggests that downstream buyers may increasingly expect traceable, standardised supply.

Under-Forest Cultivation

Yunnan intends to expand under-forest cultivation and breeding of medicinal herbs, with ecological and under-forest planting bases growing to more than six million mu. The focus varieties include sanqi, gastrodia, poria, amomum fruit, polygonatum and phellodendron.

This direction may be relevant to founders exploring land-based operations or supply agreements in forest areas. However, land use, forestry rules and local approvals are separate regulatory matters. The plan describes a provincial direction; it does not create automatic rights to use forest land. Foreign-invested enterprises should verify land and forestry compliance with local authorities and qualified advisers.

Primary Processing at Origin

The plan supports establishing processing lines at production sites in authentic herb-growing areas and at high-standard raw material bases. It also encourages linking GAP-base herbs with fresh cutting and processing, and upgrading products from primary raw materials to semi-industrial input materials.

For founders, this points to opportunities in first-stage processing and supply-chain upgrading. A China-registered company in this space would still need to consider food, drug, environmental and industrial permitting requirements, which the plan does not detail.

Higher-Value Products

Yunnan will support enterprises in building modern deep-processing lines and developing higher-value-added products, forming a series of Yunnan medicine health products. The plan also promotes research, development and industrialisation of health products such as personal care and cosmetics, and functional wellness products.

This is one of the more commercially oriented sections. Foreign founders with expertise in formulation, branding or consumer health products may see alignment with provincial goals. The plan does not, however, set out foreign investment rules, product registration pathways or incentives. Those must be checked separately.

Market Stabilisation and Risk Monitoring

The plan addresses volatility in major and scarce varieties, including sanqi, angelica and Paris polyphylla. It proposes market-based adjustment to smooth price swings. It also calls for an information monitoring and early-warning system to guard against risks such as盲目 expansion of planting and prices falling so low that they hurt farmers.

For founders, this signals that provincial authorities are conscious of supply cycles. Companies relying on these herbs should build supply contracts and inventory strategies that account for possible intervention or market adjustment.

Food-Medicine Homology Development

Yunnan plans to formulate standards for food-medicine homology raw materials, production and processing specifications, and related standards. It aims to complete cross-border registration and launch of five to ten new products and to plan a “Yunnan Medicine Food-Medicine Homology Culture Festival.”

Food-medicine homology is a regulated concept in China. Founders interested in this area should treat the plan as a signal of standard-setting activity, not as approval for any specific product.

“Yunnan Medicine Brain” and AI

The plan includes an artificial intelligence innovation application project called “Yunnan Medicine Brain.” It aims to build an intelligent application system covering the full life cycle of Chinese medicinal herbs and to develop multi-level, multi-scenario intelligent solutions in key areas.

This may create opportunities for technology providers and data-driven service companies. As with other sections, the plan describes direction rather than procurement commitments or open tenders.

Practical Takeaways for Foreign Founders

• Use the priority variety lists to assess whether your product or supply chain aligns with provincial priorities.
• Treat GAP base development and under-forest cultivation as supply-quality signals, not as substitutes for land, forestry or environmental approvals.
• Expect growing attention to origin processing and traceability if you source from Yunnan.
• Check separate rules on foreign investment, product registration, labelling and tax before committing to a China entity.
• Monitor provincial standard-setting on food-medicine homology if your products fall near that boundary.

This summary is based on information published by the relevant Chinese government website and is general information, not legal or tax advice.